<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+ 1.4a) -->
     <!-- Project:        I:\CONVER\ny12792.eep                                            -->
     <!-- Control Number: NY12792                                                          -->
     <!-- Rev Number:     8-K                                                              -->
     <!-- Client Name:    Genelabs Technologies Inc.                                       -->
     <!-- Project Name:   NY12792                                                          -->
     <!-- Firm Name:      Genelabs Technologies Inc.                                       -->
     <TITLE>8-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SECURITIES AND EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549  </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center Bold 4 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM
8-K<BR>
CURRENT REPORT
  </FONT></H1></TD></TR>
</TABLE>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to
Section 13 or 15(d) of the<BR> Securities Exchange Act of 1934  </FONT></H1></TD></TR>
</TABLE>
<BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">April 21, 2004<!-- DATE --></FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD WIDTH="600" ALIGN="CENTER"><HR NOSHADE SIZE=1 width=96%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Date of earliest event reported) </FONT></TD></TR>
</TABLE>
<BR><BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">GENELABS TECHNOLOGIES, INC.<!-- Name of Registrant --></FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD WIDTH="600" ALIGN="CENTER"><HR NOSHADE SIZE=1 width=96%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Exact name of Registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<BR><BR>

<!-- MARKER FORMAT-SHEET="8k Cover table 3" FSL="Project" -->
<Table Width=600 Cellpadding=0 Cellspacing=0 Border=0>
<tr Valign=TOP>
<td Align=CENTER Width=33%><Font Face="Times New Roman, Times, Serif" Size=2>California <!-- State--> </font></td>
<td Align=CENTER Width=34%><Font Face="Times New Roman, Times, Serif" Size=2>0-19222<!-- File No.--> </font></td>
<td Align=CENTER Width=33%><Font Face="Times New Roman, Times, Serif" Size=2>94-3010150<!-- Irs No.--> </font></td>
</tr>
<tr Valign=TOP>
<td Align=CENTER><Hr Size=1 Noshade Width=90%></td>
<td Align=CENTER><Hr Size=1 Noshade Width=90%></td>
<td Align=CENTER><Hr Size=1 Noshade Width=90%></td>
</tr>
<tr Valign=TOP>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(State of Incorporation)
</font></td>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(Commission File No.) </font></td>
<td Align=CENTER><Font Face="Times New Roman, Times, Serif" Size=2>(IRS Employer<br> Identification No.) </font></td>
</tr>
</table>
<br><BR>

<TABLE WIDTH="600" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="450" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">505 Penobscot Drive, Redwood City, California 94063<!-- ADDRESS --></FONT></TD>
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;<!-- ZIP CODE --></FONT></TD>
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD COLSPAN=4 ALIGN="CENTER"><HR NOSHADE SIZE=1 width=96%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="450" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Address of principal executive offices, including zip code) </FONT></TD>
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD>
     <TD WIDTH="50" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
<BR><BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(650) 369-9500<!-- TELEPHONE NO. --></FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD WIDTH="600" ALIGN="CENTER"><HR NOSHADE SIZE=1 width=96%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Registrant's telephone number, including area code)</FONT></TD></TR>
</TABLE>
<BR><BR>

<TABLE WIDTH="600" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><!-- FORMER NAME OR ADDRESS --></FONT></TD></TR>
<TR VALIGN="MIDDLE">
     <TD WIDTH="600" ALIGN="CENTER"><HR NOSHADE SIZE=1 width=96%></TD></TR>
<TR VALIGN="TOP">
     <TD WIDTH="600" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Former name or former address, if changed since last report) </FONT></TD></TR>
</TABLE><BR><BR><BR>

<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE>
<BR></TD></TR></TABLE>


<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ITEM
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events. </FONT></TD></TR></TABLE><BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April 21, 2004, Genelabs Technologies, Inc., a California corporation
(&#147;Registrant&#148;), announced the completion of the sale of its diagnostics business
to MP Biomedicals, LLC, pursuant to which Genelabs sold all of the outstanding common and
preferred stock of Genelabs Asia Pte. Ltd., which is the parent company of Genelabs
Diagnostics Pte. Ltd. for an aggregate purchase price of $3 million USD. A copy of the
press release announcing the sale is attached as Exhibit 99.1 hereto and is incorporated
by reference. </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ITEM
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  EXHIBITS </FONT></TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Para Hang 1" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=8%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>         99.1 </FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Press
Release of Registrant, dated April 21, 2004, entitled "Genelabs Technologies Completes
Sale of                   Diagnostics Business." </FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURE </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereto duly
authorized.  </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Company Right" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="38"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- TYPE "DATE:" HERE--> </FONT></TD>
    <TD WIDTH="238"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="254"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><!-- COMPANY -->GENELABS TECHNOLOGIES, INC. </FONT></TD>
  </TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Date By Signature" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="38"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="219"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- DATE--> </FONT></TD>
    <TD WIDTH="28"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="26"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By: </FONT></TD>
    <TD WIDTH="238"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- NAME -->/s/&nbsp;Heather Criss Keller </FONT></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD>&nbsp; </TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD> <HR NOSHADE SIZE="1"> </TD>
  </TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Name Title Right" FSL="Project" -->
<TABLE WIDTH="600" BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD WIDTH="344"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD WIDTH="42"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Name:&nbsp;</FONT></TD>
    <TD WIDTH="214"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- NAME --> Heather Criss Keller</FONT></TD>
  </TR>
   <TR VALIGN="BOTTOM">
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; </FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Title: &nbsp;</FONT></TD>
    <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp; <!-- TITLE -->Vice President
and General Counsel</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Head Left 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date:
 April 22, 2004 </FONT></P></TD></TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>


<!-- MARKER FORMAT-SHEET="Head Center 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT
INDEX </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>EXHIBIT NO.</U> </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>DESCRIPTION</U> </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Index" FSL="Project" -->
<TABLE WIDTH=600 CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=13%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1  </FONT></TD>
<TD WIDTH=3%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Press
Release of Registrant, dated April 21, 2004, entitled &#147;Genelabs
TechnologiesCompletes Sale of Diagnostics Business.&#148; </FONT></TD>
</TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Page Break Table" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><HR SIZE=5 NOSHADE COLOR="BLACK">
</TD></TR></TABLE><BR>





<!-- MARKER FORMAT-SHEET="Head Left 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT
99.1 &#150; PRESS RELEASE </FONT></P></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Right 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT
99.1 </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Center Bold 2 600" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>GENELABS
TECHNOLOGIES COMPLETES SALE<BR>
OF DIAGNOSTICS BUSINESS </FONT></H1></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>REDWOOD
CITY, Calif. &#150; April 21, 2004</B> &#150; Genelabs Technologies, Inc. (Nasdaq:GNLB)
today announced that it has completed the sale of its diagnostics business to MP
Biomedicals, LLC. In the transaction, Genelabs sold all of the outstanding common and
preferred stock of Genelabs Asia Pte. Ltd. (GLA) to MP Biomedicals. Prior to the sale,
GLA, the parent company of Genelabs Diagnostics Pte. Ltd. (GLD), was a wholly-owned
subsidiary of Genelabs Technologies. GLD is a Singapore-based company that develops,
manufactures, and markets diagnostics products primarily in Europe and Asia. </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The
divestment of our diagnostics operations reinforces our intention to maintain a sharp
focus on our core drug discovery and development operations,&#148; stated James A.D.
Smith, president and chief executive officer. &#147;The sale also provides additional
operating cash for these core operations, which include Prestara&#153;, our
investigational drug for lupus, and our efforts to discover new treatments for infection
with the hepatitis C virus. At the same time, we have provided MP Biomedicals with a new
business opportunity. I would like to thank the employees of GLD for their dedication over
the years, and wish future success to the GLD staff and to the new owners.&#148; </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent 0" FSL="Project" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genelabs
Technologies, Inc. is a biopharmaceutical company pioneering the discovery and development
of novel pharmaceutical products to improve human health. We are concentrating our
clinical development capabilities on Prestara&#153;, an investigational drug for women
with systemic lupus erythematosus and have received an approvable letter for our Prestara
New Drug Application from the U.S. Food and Drug Administration. We are concentrating our
drug discovery capabilities on novel antiviral compounds for treatment of hepatitis C
virus infections. </FONT></TD></TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Flush Left" FSL="Default" -->
<TABLE WIDTH=600 CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE=2>NOTE:
This press release contains forward-looking statements including statements regarding our
focus on our core operations of drug discovery and development and the use of our
operating cash for these operations. These forward-looking statements are based on
Genelabs&#146; current expectations and are subject to uncertainties and risks that could
cause actual results to differ materially from the statements made. Uncertainties and
risks include, without limitation, the company&#146;s capital requirements and history of
operating losses; whether the results of the company&#146;s clinical trials of
Prestara&#153; and other supporting information will be sufficient to support the approval
of Prestara&#153; by the FDA, the European Agency for Evaluation of Medicinal Products and
other regulatory authorities; delays regarding the regulatory approval process including
the timing and scope of approval received, if any; uncertainties and risks regarding
market acceptance of Prestara&#153; as a treatment for SLE; uncertainties and risks
regarding the company&#146;s ability to consummate strategic or corporate partner
transactions on favorable terms or at all; the early stage of Genelabs&#146; research
programs and uncertainties associated with the preclinical development of compounds,
including whether a compound will advance to preclinical testing, clinical trials, or
ultimately become a product, and the uncertainty of the timing of any of these; and the
validity, scope and enforceability of patents related to the company&#146;s technologies.
The active ingredient in Prestara&#153; is prasterone, the synthetic equivalent of the
androgenic hormone dehydroepiandrosterone (DHEA). Products containing DHEA are currently
being marketed by others as dietary supplements. The company has not submitted
applications for regulatory review of Prestara&#153; outside the U.S. and Europe. In
addition, neither U.S. nor other regulatory authorities have made a determination as to
the safety or efficacy of Prestara&#153; for SLE. Please see the information appearing in
the company&#146;s filings with the Securities and Exchange Commission, including the most
recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, under the captions
&#147;Risk Factors,&#148; &#147;Business Risks&#148; and &#147;Forward-Looking
Statements&#148; for more discussion regarding these uncertainties and risks and others
associated with the company&#146;s research programs, early stage of development and other
risks which may affect the company or cause actual results to differ from those included
in the forward-looking statements. Genelabs does not undertake any obligation to update
these forward-looking statements or risks to reflect events or circumstances after the
date of this release. </FONT></TD></TR></TABLE><BR>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "pal156467.htm", "description": "FORM 8-K", "secsgml_size_bytes": 19814}]
{"company-data": {"conformed-name": "GENELABS TECHNOLOGIES INC /CA", "cik": "0000874443", "assigned-sic": "2834", "irs-number": "943010150", "state-of-incorporation": "CA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19222", "film-number": "04747778"}, "business-address": {"street1": "505 PENOBSCOT DR", "city": "REDWOOD CITY", "state": "CA", "zip": "94063", "phone": "6503969500"}, "mail-address": {"street1": "505 PENOBSCOT DR", "city": "REDWOOD CITY", "state": "CA", "zip": "94063"}}
8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 21, 2004
(Date of earliest event reported)
GENELABS TECHNOLOGIES, INC.
(Exact name of Registrant as specified in its charter)
California
0-19222
94-3010150
(State of Incorporation)
(Commission File No.)
(IRS Employer
Identification No.)
505 Penobscot Drive, Redwood City, California 94063
(Address of principal executive offices, including zip code)
(650) 369-9500
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
ITEM
5.     Other Events.
On
April 21, 2004, Genelabs Technologies, Inc., a California corporation
("Registrant"), announced the completion of the sale of its diagnostics business
to MP Biomedicals, LLC, pursuant to which Genelabs sold all of the outstanding common and
preferred stock of Genelabs Asia Pte. Ltd., which is the parent company of Genelabs
Diagnostics Pte. Ltd. for an aggregate purchase price of $3 million USD. A copy of the
press release announcing the sale is attached as Exhibit 99.1 hereto and is incorporated
by reference.
ITEM
7.       EXHIBITS
99.1
Press
Release of Registrant, dated April 21, 2004, entitled "Genelabs Technologies Completes
Sale of                   Diagnostics Business."
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereto duly
authorized.
GENELABS TECHNOLOGIES, INC.
By:
/s/ Heather Criss Keller
Name:
Heather Criss Keller
Title:
Vice President
and General Counsel
Date:
 April 22, 2004
EXHIBIT
INDEX
EXHIBIT NO.
DESCRIPTION
99.1
Press
Release of Registrant, dated April 21, 2004, entitled "Genelabs
TechnologiesCompletes Sale of Diagnostics Business."
EXHIBIT
99.1 – PRESS RELEASE
EXHIBIT
99.1
GENELABS
TECHNOLOGIES COMPLETES SALE
OF DIAGNOSTICS BUSINESS
REDWOOD
CITY, Calif. – April 21, 2004
– Genelabs Technologies, Inc. (Nasdaq:GNLB)
today announced that it has completed the sale of its diagnostics business to MP
Biomedicals, LLC. In the transaction, Genelabs sold all of the outstanding common and
preferred stock of Genelabs Asia Pte. Ltd. (GLA) to MP Biomedicals. Prior to the sale,
GLA, the parent company of Genelabs Diagnostics Pte. Ltd. (GLD), was a wholly-owned
subsidiary of Genelabs Technologies. GLD is a Singapore-based company that develops,
manufactures, and markets diagnostics products primarily in Europe and Asia.
"The
divestment of our diagnostics operations reinforces our intention to maintain a sharp
focus on our core drug discovery and development operations," stated James A.D.
Smith, president and chief executive officer. "The sale also provides additional
operating cash for these core operations, which include Prestara™, our
investigational drug for lupus, and our efforts to discover new treatments for infection
with the hepatitis C virus. At the same time, we have provided MP Biomedicals with a new
business opportunity. I would like to thank the employees of GLD for their dedication over
the years, and wish future success to the GLD staff and to the new owners."
Genelabs
Technologies, Inc. is a biopharmaceutical company pioneering the discovery and development
of novel pharmaceutical products to improve human health. We are concentrating our
clinical development capabilities on Prestara™, an investigational drug for women
with systemic lupus erythematosus and have received an approvable letter for our Prestara
New Drug Application from the U.S. Food and Drug Administration. We are concentrating our
drug discovery capabilities on novel antiviral compounds for treatment of hepatitis C
virus infections.
NOTE:
This press release contains forward-looking statements including statements regarding our
focus on our core operations of drug discovery and development and the use of our
operating cash for these operations. These forward-looking statements are based on
Genelabs' current expectations and are subject to uncertainties and risks that could
cause actual results to differ materially from the statements made. Uncertainties and
risks include, without limitation, the company's capital requirements and history of
operating losses; whether the results of the company's clinical trials of
Prestara™ and other supporting information will be sufficient to support the approval
of Prestara™ by the FDA, the European Agency for Evaluation of Medicinal Products and
other regulatory authorities; delays regarding the regulatory approval process including
the timing and scope of approval received, if any; uncertainties and risks regarding
market acceptance of Prestara™ as a treatment for SLE; uncertainties and risks
regarding the company's ability to consummate strategic or corporate partner
transactions on favorable terms or at all; the early stage of Genelabs' research
programs and uncertainties associated with the preclinical development of compounds,
including whether a compound will advance to preclinical testing, clinical trials, or
ultimately become a product, and the uncertainty of the timing of any of these; and the
validity, scope and enforceability of patents related to the company's technologies.
The active ingredient in Prestara™ is prasterone, the synthetic equivalent of the
androgenic hormone dehydroepiandrosterone (DHEA). Products containing DHEA are currently
being marketed by others as dietary supplements. The company has not submitted
applications for regulatory review of Prestara™ outside the U.S. and Europe. In
addition, neither U.S. nor other regulatory authorities have made a determination as to
the safety or efficacy of Prestara™ for SLE. Please see the information appearing in
the company's filings with the Securities and Exchange Commission, including the most
recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, under the captions
"Risk Factors," "Business Risks" and "Forward-Looking
Statements" for more discussion regarding these uncertainties and risks and others
associated with the company's research programs, early stage of development and other
risks which may affect the company or cause actual results to differ from those included
in the forward-looking statements. Genelabs does not undertake any obligation to update
these forward-looking statements or risks to reflect events or circumstances after the
date of this release.